// App-Quantinova.ai

93 : Is docetaxel-prednisone (DP) feasible in frail elderly (age 75 or older) patients with castration-resistant metastatic prostate cancer (CRMPC)- GERICO10-GETUG P03 trial: A trial from elderly and genitourinary oncology UNICANCER groups.

Researchers

Presenter

  • Loic Mourey

Principal Investigators

  • Emmanuel Sevin

  • Igor Latorzeff

  • Nadine Houede

  • Jerome Meunier

  • Frank Priou

  • Gwenaelle Gravis

  • Elisabeth Carola

  • Christine Orsini

  • Thomas Filleron

Medical Centers

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Clinique Pasteur, Toulouse, France

  • Centre Hospitalier Regional dOrleans Service Oncologie Medicale, Orleans, France

  • Centre Francois Baclesse, Caen, France

  • Centre Hospitalier du Mans, Le Mans, France

  • Institut Bergonie, Bordeaux, France

  • Institut Claudius Regaud, Toulouse, France

  • UNICANCER, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Cytochrome P450 Family 3 Subfamily A Member 4

  • Cytochrome P450 Family 3 Subfamily A Member 5

Drug/Treatment

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved